Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system

7 March 2023

LungLife AI, Inc.
(the “Company” or “LungLife”)

 Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system

Data strongly support payor coverage of indeterminate lung nodule evaluation using LungLB® in peer-reviewed publication in the Journal of Medical Economics.

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that further to its announcement on 27 February 2023, the final version of the health economics publication is now available. There have been no changes to the results or conclusions, which show LungLB® is projected to be a cost-effective solution for US insurers covering individuals with indeterminate lung nodules.

The publication can now be accessed here: Journal of Medical Economics Vol 26

For the full announcement, click HERE.